VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Discovery

Key Highlights

• VolitionRx (VNRX) shares skyrocketed more than 70% during pre-market hours Wednesday
• The biotech firm achieved greater than 99% purity in isolating circulating tumor DNA (ctDNA) from blood
• Capture-Seq technology combines physical enrichment with bioinformatics in a dual-step approach
• Blind study results revealed perfect 49/49 cancer detection rate in first cohort, 13/14 in second
• VolitionRx estimates a combined market opportunity of approximately $36 billion and is pursuing licensing partnerships

Shares of VNRX exploded more than 70% higher in Wednesday’s pre-market session following VolitionRx’s announcement of what the company characterized as a breakthrough achievement in liquid biopsy innovation.

VolitionRx Limited, VNRX

According to the announcement, VolitionRx successfully extracted circulating tumor-derived DNA (ctDNA) from blood specimens with purity exceeding 99%. This represents a remarkably clean isolation, with virtually all non-cancerous DNA eliminated from the sample.

Liquid biopsy technology has long faced a fundamental obstacle: the vast majority of cell-free DNA in bloodstreams originates from normal, healthy cells rather than malignant ones. Extracting a clear cancer signal from this biological noise has proven exceptionally challenging. VolitionRx claims its innovative approach overcomes this hurdle.

The company’s Capture-Seq methodology employs a dual-phase process. Initially, it physically concentrates the sample. Subsequently, sophisticated bioinformatics algorithms eliminate residual background interference. According to VolitionRx, this produces a dataset with tumor DNA purity exceeding 99%.

Jake Micallef, the company’s Chief Scientific Officer, characterized the development as unprecedented globally. He explained that CTCF-bound DNA — the particular DNA signature this technique identifies — appears virtually nonexistent in healthy plasma but constitutes nearly the entire cancer-derived component in affected patients.

Blind Study Detection Performance

VolitionRx disclosed findings from two separate blinded cohort investigations. The initial cohort demonstrated detection of all 49 cancer cases tested. The second cohort identified 13 of 14 cases.

These figures represent preliminary data, and the cohort sizes remain limited. More extensive clinical trials will be essential before any commercial deployment. Additionally, the methodology captures only a portion of ctDNA, suggesting some tumor-derived fragments might escape detection.

The company has submitted a revised manuscript to Research Square, a preprint publication platform. The research has not yet undergone peer review, which represents a crucial validation step within the scientific establishment.

Commercial Opportunity and Business Strategy

VolitionRx referenced a total addressable market valued at roughly $36 billion, encompassing both multi-cancer early detection (MCED) applications and minimal residual disease (MRD) surveillance.

According to the company, it is presently engaged in substantive negotiations with prospective diagnostic licensing partners. No formal agreements have been disclosed to date.

VNRX shares were positioned to close above the 100-day moving average for the first occasion since October 8, 2025, assuming pre-market momentum carried through to the regular trading session.

The revised preprint manuscript is anticipated to appear on Research Square in the near term, per company statements.

The post VolitionRx (VNRX) Stock Soars 70% on Revolutionary Cancer DNA Discovery appeared first on Blockonomi.